戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 osal bleeding and ulceration, petechiae, and gingival hyperplasia.
2 ingival tissue could provide a mechanism for gingival hyperplasia.
3 g amlodipine and determine the prevalence of gingival hyperplasia.
4 h, intrapulpal calcifications, and localized gingival hyperplasia.
5  channel blockers are known to contribute to gingival hyperplasia.
6 hat amlodipine, 5 mg per day, did not induce gingival hyperplasia.
7 eered to undergo a screening examination for gingival hyperplasia.
8  lymphoproliferative disorders presenting as gingival hyperplasia.
9                          Hirsutism (94%) and gingival hyperplasia (51%) occurred more frequently in c
10 eported immunosuppression-induced hirsutism, gingival hyperplasia, acne, alopecia, or cushingoid faci
11 asure the HQL impact of side effects such as gingival hyperplasia and facial hirsutism on physical ap
12 iated with Amelogenesis Imperfecta (AI) with gingival hyperplasia and nephrocalcinosis, while FAM20C
13 ecipients is associated with hypertrichosis, gingival hyperplasia, and hypercholesterolemia.
14 et, the molecular mechanisms of drug-induced gingival hyperplasia are unknown although it has been po
15 per presents an older patient with recurrent gingival hyperplasia due to plasminogen deficiency (hypo
16                                    Recurrent gingival hyperplasia due to plasminogen deficiency (hypo
17                               A diagnosis of gingival hyperplasia due to plasminogen deficiency (hypo
18                                    Recurrent gingival hyperplasia due to plasminogen deficiency is a
19                                       Severe gingival hyperplasia (GH) is one of the most frequent si
20             Patients with nifedipine-induced gingival hyperplasia (GH) often require continued calciu
21  indicating that amlodipine may also promote gingival hyperplasia; however, no data have been reporte
22                                         Mean gingival hyperplasia index decreased from 24 to 6; mean
23                                              Gingival hyperplasia index, total cholesterol, and blood
24                          Juvenile spongiotic gingival hyperplasia (JSGH) is a distinct clinicopatholo
25       A common side effect of PHT therapy is gingival hyperplasia, occasionally so severe that it req
26  wounds, gingivitis and periodontal disease, gingival hyperplasia, vestibular obliteration, cheilitis
27 osomal-recessive syndrome associating AI and gingival hyperplasia was recently reported.
28 crodontism of primary teeth, and generalized gingival hyperplasia, whereas Sprengel deformity of scap
29  several undesirable side effects, including gingival hyperplasia, which occurs in up to 70% of patie
30 e periods were histologically reported to be gingival hyperplasia with chronic inflammation.